Wechselwirkungen · Gencebok
Gencebok 10 mg/ml solution for infusion · Abschnitt 4.5 · PDF-Seite 5
HOS-147386 · Präparat HOS-099648
Although few data exist on interactions of caffeine with other active substances in preterm newborn infants, lower doses of caffeine citrate may be needed following co-administration of active substances which are reported to decrease caffeine elimination in adults (e.g., cimetidine and ketoconazole) and higher caffeine citrate doses may be needed following co-administration of active substances that increase caffeine elimination (e.g., phenobarbital and phenytoin). Where doubt exists about possible interactions, plasma caffeine concentrations should be measured. As bacterial overgrowth in the gut is associated with the development of necrotising enterocolitis, co- administration of caffeine citrate with medicinal products that suppress gastric acid secretion (antihistamine H2 receptor blockers or proton-pump inhibitors) may in theory increase the risk of necrotising enterocolitis (see section 4.4 and 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) cimetidine (HOS-085835) ketoconazole (HOS-084513) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-12T11:47:00Z · SHA-256 6e3fcdb632e35a419e60a0205279199521acdd7f49db6bbb54b87cd49828401f · Passage ca67319c3041bcd53047f858aef2b5a5155150b7191289ea8a5bffd7b3fd1096 · Zeichen 496–1416 im Abschnitt